Loading clinical trials...
Loading clinical trials...
A MULTICENTER, OPEN-LABEL, SINGLE-ARM STUDY TO EVALUATE LONG-TERM SAFETY AND TOLERABILITY OF BRIVARACETAM IN STUDY PARTICIPANTS WITH CHILDHOOD ABSENCE EPILEPSY OR JUVENILE ABSENCE EPILEPSY
Conditions
Interventions
Brivaracetam Film-coated tablet
Brivaracetam oral solution
Locations
23
United States
Ep0224 50140
Birmingham, Alabama, United States
Ep0224 50639
Orange, California, United States
Ep0224 50268
Miami, Florida, United States
Ep0224 50638
New Brunswick, New Jersey, United States
Ep0224 50640
Winston-Salem, North Carolina, United States
Ep0224 20321
Tbilisi, Georgia
Start Date
July 10, 2024
Primary Completion Date
March 1, 2030
Completion Date
March 1, 2030
Last Updated
April 13, 2026
Lead Sponsor
UCB Biopharma SRL
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions